Suppr超能文献

凝血因子XIa上因子IX底物结合位点的鉴定与化学合成

Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa.

作者信息

Baglia F A, Jameson B A, Walsh P N

机构信息

Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.

出版信息

J Biol Chem. 1991 Dec 15;266(35):24190-7.

PMID:1748688
Abstract

We have previously used monoclonal antibodies to identify an epitope on the heavy chain of factor XIa that is a substrate-binding site for factor IX (Sinha, D., Seaman, F.S., and Walsh, P.N. (1987) Biochemistry 26, 3768-3775; Baglia, F.A., Sinha, D., and Walsh, P.N. (1989) Blood 74, 244-251). To define the factor XIa domain that binds factor IX, we have now screened a panel of factor XI heavy chain-derived synthetic peptides for their capacity to inhibit the formation of an activation peptide reflecting factor IX activation by factor XIa. Peptide Asn145-Ala176 (which is located in the second tandem repeat or A2 domain of the factor XI heavy chain) is a competitive inhibitor of factor IX activation by factor XIa with a Ki of 30 nM, whereas structurally similar peptides in the A1, A3, and A4 domains were required at 10-1000-fold higher concentrations for similar effects, and a synthetic peptide identical with a highly homologous region of the heavy chain A2 domain of prekallikrein (Tyr143-Ala176) had no effect on factor IX activation by factor XIa. Because detailed structural information is lacking, a potential three-dimensional structure for the factor XI A2 domain was calculated based on its sequence information in conjunction with previously determined structural constraints. The resulting structure depicted three juxtaposed beta-stranded stem-loops that, based on biological information, constitute a candidate surface for contact with factor IX. The A2 model was therefore used as a template in the rational design of three synthetic peptides (Ala134-Ile146 (peptide a), Leu148-Arg159 (peptide b), and Ile160-Leu172 (peptide c]. When peptides a and b or a and c were added together and the activation of factor IX by factor XIa was examined, a synergistic inhibitory effect was observed, compared with each peptide added individually, whereas peptides b and c showed additive effects. Our data suggest that the sequence of amino acids from Ala134 through Leu172 of the heavy chain of factor XI contains three antiparallel beta-strands connected by beta-turns that together comprise a continuous surface utilized for the binding of factor IX.

摘要

我们之前使用单克隆抗体鉴定了因子Xla重链上的一个表位,该表位是因子IX的底物结合位点(辛哈,D.,西曼,F.S.,和沃尔什,P.N.(1987年)《生物化学》26,3768 - 3775;巴利亚,F.A.,辛哈,D.,和沃尔什,P.N.(1989年)《血液》74,244 - 251)。为了确定结合因子IX的因子Xla结构域,我们现在筛选了一组源自因子XI重链的合成肽,以检测它们抑制反映因子IX被因子Xla激活的激活肽形成的能力。肽Asn145 - Ala176(位于因子XI重链的第二个串联重复序列或A2结构域中)是因子IX被因子Xla激活的竞争性抑制剂,其Ki为30 nM,而A1、A3和A4结构域中结构相似的肽要产生类似效果则需要高10 - 1000倍的浓度,并且与前激肽释放酶重链A2结构域的高度同源区域相同的合成肽(Tyr143 - Ala176)对因子IX被因子Xla激活没有影响。由于缺乏详细的结构信息,基于因子XI A2结构域的序列信息并结合先前确定的结构限制条件,计算了其潜在的三维结构。所得结构描绘了三个并列的β - 链茎环,根据生物学信息,它们构成了与因子IX接触的候选表面。因此,A2模型被用作合理设计三种合成肽(Ala134 - Ile146(肽a)、Leu148 - Arg159(肽b)和Ile160 - Leu172(肽c))的模板。当将肽a和b或肽a和c一起添加并检测因子IX被因子Xla激活的情况时,与单独添加每种肽相比,观察到了协同抑制作用,而肽b和c表现出相加作用。我们的数据表明,因子XI重链中从Ala134到Leu172的氨基酸序列包含由β - 转角连接的三条反平行β - 链,它们共同构成了用于结合因子IX的连续表面。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验